Antitumoral Effects of D-Fraction from Grifola Frondosa (Maitake) Mushroom in Breast Cancer

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al.: Global cancer statistics. CA Cancer J Clin 61, 69–90, 2011.
   PubMed Web of Science ®Google Scholar
• GLOBOCAN: International Agency for Research on Cancer (IARC). GLOBOCAN 2012: estimates of the incidence of, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/. (Accessed November 2, 2015).
   Google Scholar
• Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608, 1–22, 2007.
   PubMed Web of Science ®Google Scholar
• De Silva DD, Rapior S, Fons F, Bahkali AH, et al.: Medicinal mushrooms in supportive cancer therapies: an approach to anti-cancer effects and putative mechanisms of action. Fungal Diversity 55, 1–35, 2012.
   Web of Science ®Google Scholar
• Petrova RD, Reznick AZ, Wasser SP, Denchev CM, Nevo E, et al.: Fungal metabolites modulating NF-kappaB activity: an approach to cancer therapy and chemoprevention (review). Oncol Rep 19, 299–308, 2008.
   PubMed Web of Science ®Google Scholar
• Leung MY, Liu C, Koon JC, and Fung KP: Polysaccharide biological response modifiers. Immunol Lett 105, 101–114, 2006.
   PubMed Web of Science ®Google Scholar
• Akramiene D, Kondrotas A, Didziapetriene J, and Kevelaitis E: Effects of β-glucans on the immune system. Medicina (Kaunas) 43, 597–606, 2007.
   PubMed Web of Science ®Google Scholar
• Brown GD and Gordon S: Immune recognition of fungal β-glucans. Cell Microbiol 7, 471–479, 2005.
   PubMed Web of Science ®Google Scholar
• Chan GC, Chan WK, and Sze DM: The effects of β-glucan on human immune and cancer cells. J Hematol Oncol 2, 25, 2009.
   PubMed Web of Science ®Google Scholar
• Zhang M, Cui SW, Cheung PCK, and Wang Q: Antitumor polysaccharides from mushrooms: a review on their isolation process, structural characteristics and antitumor activity. Trends Food Sci Technol 18, 4–19, 2007.
   Web of Science ®Google Scholar
• Lull C, Wichers HJ, and Savelkoul HF: Antiinflammatory and immunomodulating properties of fungal metabolites. Mediators Inflamm 2005, 63–80, 2005.
   PubMed Web of Science ®Google Scholar
• Mayell M: Maitake extracts and their therapeutic potential. Altern Med Rev 6, 48–60, 2001.
   PubMedGoogle Scholar
• Hishida I, Nanba H, and Kuroda H: Antitumor activity exhibited by orally administered extract from fruit body of Grifola frondosa (maitake). Chem Pharm Bull (Tokyo) 36, 1819–1827, 1988.
   PubMed Web of Science ®Google Scholar
• Inoue A, Kodama N, and Nanba H: Effect of maitake (Grifola frondosa) D-Fraction on the control of the T lymph node Th-1/Th-2 proportion. Biol Pharm Bull 25, 536–540, 2002.
   PubMed Web of Science ®Google Scholar
• Kodama N, Yamada M, and Nanba H: Addition of Maitake D-fraction reduces the effective dosage of vancomycin for the treatment of Listeria-infected mice. Jpn J Pharmacol 87, 327–332, 2001.
   PubMedGoogle Scholar
• Kodama N, Komuta K, Sakai N, and Nanba H: Effects of D-Fraction, a polysaccharide from Grifola frondosa on tumor growth involve activation of NK cells. Biol Pharm Bull 25, 1647–1650, 2002.
   PubMed Web of Science ®Google Scholar
• Sanzen I, Imanishi N, Takamatsu N, Konosu S, Mantani N, et al.: Nitric oxide-mediated antitumor activity induced by the extract from Grifola frondosa (Maitake mushroom) in a macrophage cell line, RAW264.7. J Exp Clin Cancer Res 20, 591–597, 2001.
   PubMed Web of Science ®Google Scholar
• Kodama N, Asakawa A, Inui A, Masuda Y, and Nanba H: Enhancement of cytotoxicity of NK cells by D-Fraction, a polysaccharide from Grifola frondosa. Oncol Rep 13, 497–502, 2005.
   PubMed Web of Science ®Google Scholar
• Harada N, Kodama N, and Nanba H: Relationship between dendritic cells and the D-fraction-induced Th-1 dominant response in BALB/c tumor-bearing mice. Cancer Lett 192, 181–187, 2003.
   PubMed Web of Science ®Google Scholar
• Kodama N, Harada N, and Nanba H: A polysaccharide, extract from Grifola frondosa, induces Th-1 dominant responses in carcinoma-bearing BALB/c mice. Jpn J Pharmacol 90, 357–360, 2002.
   PubMedGoogle Scholar
• Fullerton SA, Samadi AA, Tortorelis DG, Choudhury MS, Mallouh C, et al.: Induction of apoptosis in human prostatic cancer cells with beta-glucan (Maitake mushroom polysaccharide). Mol Urol 4, 7–13, 2000.
   PubMedGoogle Scholar
• Konno S: Synergistic potentiation of D-fraction with vitamin C as possible alternative approach for cancer therapy. Int J Gen Med 2, 91–108, 2009.
   PubMedGoogle Scholar
• Soares R, Meireles M, Rocha A, Pirraco A, Obiol D, et al.: Maitake (D Fraction) mushroom extract induces apoptosis in breast cancer cells by BAK-1 gene activation. J Med Food 14, 563–572, 2011.
   PubMed Web of Science ®Google Scholar
• Alexander B, Fishman AI, Eshghi M, Choudhury M, and Konno S: Induction of cell death in renal cell carcinoma with combination of D-fraction and vitamin C. Integr Cancer Ther 12, 442–448, 2013.
   PubMed Web of Science ®Google Scholar
• Degen M, Alexander B, Choudhury M, Eshghi M, and Konno S: Alternative therapeutic approach to renal-cell carcinoma: induction of apoptosis with combination of vitamin K3 and D-fraction. J Endourol 27, 1499–1503, 2013.
   PubMed Web of Science ®Google Scholar
• Alonso EN, Orozco M, Eloy Nieto A, and Balogh GA: Genes related to suppression of malignant phenotype induced by Maitake D-Fraction in breast cancer cells. J Med Food 16, 602–617, 2013.
   PubMed Web of Science ®Google Scholar
• Urtreger A, Ladeda V, Puricelli L, Rivelli A, Vidal M, et al.: Modulation of fibronectin expression and proteolytic activity associated with the invasive and metastatic phenotype in two new murine mammary tumor cell lines. Int J Oncol 11, 489–496, 1997.
   PubMed Web of Science ®Google Scholar
• Carnevale RP, Proietti CJ, Salatino M, Urtreger A, Peluffo G, et al.: Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Mol Endocrinol 21, 1335–1358, 2007.
   PubMed Web of Science ®Google Scholar
• Puricelli L, Proietti CJ, Labriola L, Salatino M, Balañá ME, et al.: Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells. Int J Cancer 100, 642–653, 2002.
   PubMed Web of Science ®Google Scholar
• Fermento ME, Gandini NA, Salomón DG, Ferronato MJ, Vitale CA, et al.: Inhibition of p300 suppresses growth of breast cancer. Role of p300 subcellular localization. Exp Mol Pathol 97, 411–424, 2014.
   PubMed Web of Science ®Google Scholar
• Gandini NA, Fermento ME, Salomón DG, Obiol DJ, Andrés NC, et al.: Heme oxygenase-1 expression in human gliomas and its correlation with poor prognosis in patients with astrocytoma. Tumour Biol 35, 2803–2815, 2014.
   PubMed Web of Science ®Google Scholar
• Petit V, Boyer B, Lentz D, Turner CE, Thiery JP, et al.: Phosphorylation of tyrosine residues 31 and 118 on paxillin regulates cell migration through an association with CRK in NBT-II cells. J Cell Biol 148, 957–970, 2000.
   PubMed Web of Science ®Google Scholar
• Gueron G, Giudice J, Valacco P, Paez A, Elguero B, et al.: Heme-oxygenase-1 implications in cell morphology and the adhesive behavior of prostate cancer cells. Oncotarget 5, 4087–4102, 2014.
   PubMed Web of Science ®Google Scholar
• Gandini NA, Fermento ME, Salomón DG, Blasco J, Patel V, et al.: Nuclear localization of heme oxygenase-1 is associated with tumor progression of head and neck squamous cell carcinomas. Exp Mol Pathol 93, 237–245, 2012.
   PubMed Web of Science ®Google Scholar
• Urtreger AJ, Grossoni VC, Falbo KB, Kazanietz MG, Bal de Kier Joffé ED: Atypical protein kinase C-zeta modulates clonogenicity, motility, and secretion of proteolytic enzymes in murine mammary cells. Mol Carcinog 42, 29–39, 2005.
   PubMed Web of Science ®Google Scholar
• de Matos DC, de Ribeiro LC, Tansini A, Ferreira LS, et al.: Immunological response in mice bearing LM3 breast tumor undergoing pulchellin treatment. BMC Complement Altern Med 12, 107, 2012.
   PubMed Web of Science ®Google Scholar
• Facchinetti MM, Gandini NA, Fermento ME, Sterin-Speziale NB, Ji Y, et al. The expression of sphingosine kinase-1 in head and neck carcinoma. Cells Tissues Organs 192, 314–324, 2010.
   PubMed Web of Science ®Google Scholar
• Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8, 138–140, 1987.
   PubMed Web of Science ®Google Scholar
• Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100, 57–70, 2000.
   PubMed Web of Science ®Google Scholar
• Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ, et al.: The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 4, 761–767, 2009.
   PubMed Web of Science ®Google Scholar
• Xu W, Yang Z, and Lu N: A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr 9, 317–324, 2015.
   PubMed Web of Science ®Google Scholar
• Yang SX, Polley E, and Lipkowitz S: New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev 45, 87–96, 2016.
   PubMed Web of Science ®Google Scholar
• Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science 331, 1559–1564, 2011.
   PubMed Web of Science ®Google Scholar
• Bertolesi G, Eijan AM, Calvo JC, and Lauria de Cidre L: Heparin increases the adhesion of murine mammary adenocarcinoma cells (LM3). Correlation with the presence of heparin receptors on cell surface. J Biol Regul Homeost Agents 19, 33–40, 2005.
   PubMed Web of Science ®Google Scholar
• Lambrechts A, Van Troys M, and Ampe C: The actin cytoskeleton in normal and pathological cell motility. Int J Biochem Cell Biol 36, 1890–1909, 2004.
   PubMed Web of Science ®Google Scholar
• Yamazaki D, Kurisu S, and Takenawa T: Regulation of cancer cell motility through actin reorganization. Cancer Sci 96, 379–386, 2005.
   PubMed Web of Science ®Google Scholar
• Toth M and Fridman R: Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol Med 57, 163–174, 2001.
   PubMedGoogle Scholar
• Vihinen P and Kähäri VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99, 157–166, 2002.
   PubMed Web of Science ®Google Scholar
• Yadav L, Puri N, Rastogi V, Satpute P, Ahmad R, et al.: Matrix metalloproteinases and cancer - roles in threat and therapy. Asian Pac J Cancer Prev 15, 1085–1091, 2014.
   PubMedGoogle Scholar
• Roy DM and Walsh LA: Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors. Breast Cancer (Dove Med Press) 6, 81–91, 2014.
   PubMedGoogle Scholar
• Chandolia B, Basu SK, and Kumar M: Can MMP-9 be a prognosticator marker for oral squamous cell carcinoma? J Clin Diagn Res 10, ZC09–13, 2016.
   PubMedGoogle Scholar
• Christofori G: New signals from the invasive front. Nature 441, 444–450, 2006.
   PubMed Web of Science ®Google Scholar
• Baum B and Georgiou M: Dynamics of adherens junctions in epithelial establishment, maintenance, and remodeling. J Cell Biol 192, 907–917, 2011.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139, 871–890, 2009.
   PubMed Web of Science ®Google Scholar
• Mallini P, Lennard T, Kirby J, and Meeson A: Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev 40, 341–348, 2014.
   PubMed Web of Science ®Google Scholar
• Ferreira IC, Vaz JA, Vasconcelos MH, and Marins A: Compounds from wild mushrooms with antitumor potential. Anticancer Agents Med Chem 10, 424–436, 2010.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Biswas G, Basu SK, and Acharya K: Antineoplastic effect of mushrooms: a review. AJCS 5, 904–911, 2011.
   Google Scholar
• Petrova RD, Wasser SP, Mahajna J, Denchev CM, and Nevo E: Potential role of medicinal mushrooms in breast cancer treatment: current knowledge and future perspectives. Int J Med Mushr 7, 141–155, 2005.
   Google Scholar
• Zaidman BZ, Yassin M, Mahajna J, and Wasser SP: Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol 67, 453–468, 2005.
   PubMed Web of Science ®Google Scholar
• Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144, 646–674, 2011.
   PubMed Web of Science ®Google Scholar
• Horwitz KB, Costlow ME, and McGuire WL: MCF-7; a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids 26, 785–795, 1975.
   PubMed Web of Science ®Google Scholar
• Subik K, Lee JF, Baxter L, Strzepek T, Costello D, et al.: The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl) 4, 35–41, 2010.
   PubMedGoogle Scholar
• Jafaar ZM, Litchfield LM, Ivanova MM, Radde BN, Al-Rayyan N, et al.: β-D-glucan inhibits endocrine-resistant breast cancer cell proliferation and alters gene expression. Int J Oncol 44, 1365–1375, 2014.
   PubMed Web of Science ®Google Scholar
• Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2, 489–501, 2002.
   PubMed Web of Science ®Google Scholar
• Saji M and Ringel MD: The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 321, 20–28, 2010.
   PubMed Web of Science ®Google Scholar
• Zhang H, Xiong Z, Wang J, Zhang S, Lei L, et al.: Glucagon-like peptide-1 protects cardiomyocytes from advanced oxidation protein product-induced apoptosis via the PI3K/Akt/Bad signaling pathway. Mol Med Rep 13, 1593–1601, 2016.
   PubMed Web of Science ®Google Scholar
• Badve S and Nakshatri H: Role of AKT isotypes in breast cancer. J Pathol 229, e1, 2013.
   PubMed Web of Science ®Google Scholar
• Urtreger A, Porro F, Puricelli L, Werbajh S, Baralle FE, et al.: Expression of RGD minus fibronectin that does not form extracellular matrix fibrils is sufficient to decrease tumor metastasis. Int J Cancer 78, 233–241, 1998.
   PubMed Web of Science ®Google Scholar
• Olson MF and Sahai E: The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis 26, 273–287, 2009.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Maguire TM, Hill A, McDermott E, and O'Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2, 252–257, 2000.
   PubMed Web of Science ®Google Scholar
• Jezierska A and Motyl T: Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 15, RA32–40, 2009.
   PubMed Web of Science ®Google Scholar
• Talvensaari-Mattila A, Pääkkö P, and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 89, 1270–1275, 2003.
   PubMed Web of Science ®Google Scholar